Research programme: chimeric antigen receptor T-cell therapies - Shire/Precision Biosciences

Drug Profile

Research programme: chimeric antigen receptor T-cell therapies - Shire/Precision Biosciences

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxalta; Precision Biosciences
  • Developer Shire
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 07 Mar 2016 Preclinical trials in Cancer in USA (Parenteral) (Baxalta pipeline, March 2016)
  • 25 Feb 2016 Baxalta and Precision Biosciences agree to co-develop chimeric antigen receptor T-cell therapies in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top